N/A N=19 Visualizing Vascular Mechanisms of Salt Sensitivity
Obesity · Cardiovascular Risk Factor · Salt; Excess
Primary: Mean Arterial Blood Pressure Following High-salt Diet and Low-salt Diet — 83.3; 89.5 mmHg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=59 Tissue Sodium in Pre-hypertensive Patients
Hypertension
Primary: Change in Tissue Sodium Concentration Measured Using Sodium Magnetic Resonance Imaging (NaMRI) — -0.202; 0.430; -1.745; -0.407 mmol/L
N/A N=12 Central Sodium Sensing: Implications for Blood Pressure Regulation
Salt Sensitivity of Blood Pressure
Primary: Functional Connectivity Between the Subfornical Organ and Organum Vasculosum of the Lamina Terminalis (Z-score) — 0.258490; 0.359145; 0.207372; 0.169055 z-score
Phase 4 N=90 Mineralocorticoid Receptor (MR) Antagonist (Eplerenone) vs Amlodipine and STRIATIN
Hypertension · Genetics Hypertension
Primary: Systolic /Diastolic Supine Morning Liberal Salt Automated Blood Pressure — 144.2; 148.5; 86.0; 91.4 mm hg — p=0.823
Phase 2 N=14 The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension
Hypertension
Primary: Muscle Sympathetic Nerve Activity at Rest — 41; 43.8 bursts/minute
Phase 4 N=132 Effect of High and Low Sodium Diets on Blood Pressure in Hypertensive Patients Treated With Aliskiren
Hypertension
Primary: Mean 24 Hour Ambulatory Systolic Blood Pressure (MASBP) in Systolic Hypertensive Patients Treated With Aliskiren (300 mg) for 4 Weeks on a High Sodium Diet Versus 4…
N/A N=14 Effects of the Dietary Approaches to Stop Hypertension(DASH) Sodium-restricted Diet in Diastolic Heart Failure
Diastolic Heart Failure · Hypertensive Heart Disease
Primary: Brachial Artery Flow-mediated Dilation (FMD) — 5; 8 % dilation — p=.17
N/A N=92 Renin-angiotensin-aldosterone System Polymorphisms in Resistant Hypertension and Adverse Cardiovascular Events
Systemic Arterial Hypertension · Hypertension Resistant to Conventional Therapy · Myocardial Infarction
Primary: Strokes, Either Fatal or Nonfatal — 24; 7 participants — p=0.19
Phase 2 N=72 Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension
Salt-sensitive Hypertension
Primary: Cumulative Sodium Excretion (Natriuresis) at Day 1 — 61.26; 37.13; 188.87; 138.92 mmol
N/A N=17 Etiology of Sleep Apnea-related Hyperaldosteronism - BP Treatment
Obstructive Sleep Apnea · Resistant Hypertension · Hyperaldosteronism
Primary: Severity of Obstructive Sleep Apnea — -18.3; 7.0 events/hour
Phase 2 N=7 Mechanisms of Refractory Hypertension (Reserpine)
Refractory Hypertension
Primary: Change Ambulatory Systolic Blood Pressure — -29.3 mmHg
N/A N=27 Effect of Dietary Sodium Intake on Vascular Endothelium
Postural Tachycardia Syndrome (POTS)
Primary: FMD (% Change) — 12.75; 11.65; 11.43; 12.75 percentage of change
Phase 3 N=992 SAALT: Subtracting Salt and Adding Losartan Trial (0954A-335)
Hypertension
Primary: Number of Patients Achieving Target Blood Pressure at Week 14 From Baseline — 276; 270; 116; 87 Participants — p=0.118
Phase 4 N=24 Nebivolol Versus Metoprolol: Sodium Sensitivity
Hypertension
Primary: Change in 24-hour Mean Systolic Blood Pressure by ABPM From Day 5 of Low Sodium to Day 10 of High Sodium — 7.7; 9.3 mmHg
N/A N=38 Dietary Salt in Postural Tachycardia Syndrome
Postural Orthostatic Tachycardia Syndrome
Primary: Plasma Volume — 2805; 3032; 2362; 2633 mL
N/A N=17 Efficacy of Dietary Sodium Restriction of Improving Vascular Endothelial Function in Middle Aged and Older Adults
Hypertension
Primary: Improved Flow Mediated Dilation — 3.57; 6.01 percentage dilation
Phase 3 N=114 Irbesartan and Atenolol in Hypertensive Heart Disease
Hypertension
Primary: Changes in Left Ventricular Mass Index — -1; -9; -6; -14 g/m^2
N/A N=36 Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African Americans Study (GENE-FORECAST): Sodium Intervention Trial (SIT)
Cardiovascular Disease
Primary: Mean Change in Vascular Function Measured by Pulse Wave Velocity — 7.08; 7.13; 7.34; 7.07 m/s — p=0.98
Phase 4 N=256 Effects of Low Sodium Intake on the Anti-proteinuric Efficacy in Hypertensive Patient With Olmesartan
Hypertension · Chronic Kidney Disease · Microalbuminuria
Primary: ∆Albuminuria by 24-hour Urine Protein Excretion — 483.5; 569.9; 487.3; 417.4 mg/day — p=0.006
Phase 2 N=32 Sodium Excretion of LCZ696 in Patients With Hypertension; Heart Failure and Healthy Volunteers
Hypertension
Primary: 24-hour Urinary Sodium Excretion — 220.58; 198.73; 177.40; 146.18 mmol/24 hours
Phase 4 N=12 The Role of COX-2 Inhibition in Salt Sensitivity of Blood Pressure
Hypertension
Primary: Mean Arterial Pressure — 88; 87; 87; 87 mm Hg
Phase 4 N=14 A Pilot Study of Chlorthalidone Among Patients With Poorly Controlled Hypertension and CKD
Chronic Kidney Disease · Poorly-Controlled Hypertension
Primary: Change of Systolic Ambulatory Blood Pressure From Baseline to 12 Weeks — -10.5 mmHg — p=0.01
N/A N=126 Blood Pressure in Dialysis Patients
Hypertension · Renal Failure Chronic Requiring Hemodialysis · Blood Pressure
Primary: Number of Participants Assessed for Intensive (110-140 mm Hg) and Standard (155-165mm Hg) Pre-dialysis Standardized BP Goal — 62; 64 participants
Phase 2 N=160 Chlorthalidone in Chronic Kidney Disease
Renal Insufficiency, Chronic · Hypertension
Primary: Change From Baseline to 12 Weeks in Systolic Ambulatory Blood Pressure in the Chlorthalidone Group Compared to Placebo. — -11.0; -0.5 mm Hg
Phase 4 N=488 Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension
Stage 2 Systolic Hypertension
Primary: Change in Mean Sitting Systolic Blood Pressure After 6 Weeks — 166.8; 168.5; 135.5; 142.5 mmHg
N/A N=139 Trial of Dialysate Sodium in Chronic Hospitalized Hemodialysis Patients
Intra-dialytic Hypotension
Primary: Change in Intra-dialytic Decline in Systolic Blood Pressure — 26; 23 mm Hg
N/A N=38 Dietary Sodium's Effect on Urinary Sodium and Dopamine Excretion in Patients With Postural Tachycardia Syndrome
Postural Orthostatic Tachycardia Syndrome
Primary: 24hr Urinary Sodium — 16.8; 280; 14.7; 245 milliequivalents
N/A N=32 Mechanisms and Phenotypes of Hypertension in Patients in Chronic Hemodialysis
Arterial Hypertension · Hemodialysis
Primary: Cardiac Output — 3.9; 4.10; 4.6 L/min
Phase 4 N=124 Salt Loading and Thiazide Intervention Study
Hypertension
Primary: Blood Pressure Change During Salt Loading — -25.5; 34.6; 23.2; -41.4 mmHg — p=>0.05
Phase 4 N=47 Effects of Thiazide Diuretics on Sympathetic Nervous System in Hypertension
Hypertension
Primary: Sympathetic Nerve Activity — 46; 40; 49; 42 bursts/min